Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Del Rosso, James Q. [2 ]
Alonso-Llamazares, Javier [3 ]
Lattouf, Mark [4 ]
Jacobson, Abby [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Thomas Dermatol, JDR Dermatol Res, Las Vegas, NV USA
[3] Miami Vet Affairs Healthcare Syst, Miami, FL USA
[4] Ortho Dermatol, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27124
引用
收藏
页码：AB130 / AB130
页数：1
相关论文
共 50 条
  • [1] Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
    Reddy, Vidhatha
    Myers, Bridget
    Yang, Eric J.
    Bhutani, Tina
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 391 - 398
  • [2] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    [J]. CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [3] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Nicholas D. Brownstone
    Tina Bhutani
    John Koo
    [J]. Current Dermatology Reports, 2021, 10 : 21 - 25
  • [4] Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis
    Alexis, Andrew F.
    Yamauchi, Paul S.
    Desai, Seemal R.
    Khaselev, Nelly
    Lin, Tina
    [J]. CUTIS, 2020, 105 (03): : 150 - +
  • [5] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
  • [6] Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)
    Gold, Linda Stein
    Lain, Edward
    Bagel, Jerry
    Jacobson, Abby
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB156 - AB156
  • [7] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [8] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
    Desai, Seemal R.
    Alexis, Andrew F.
    Jacobson, Abby
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
  • [9] An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
    Ozyurekoglu, Elif
    Kircik, Leon H.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (11) : 1191 - 1194
  • [10] Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Gold, Linda Stein
    Del Rosso, James Q.
    Green, Lawrence
    Jacobson, Abby
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2068 - 2074
12345